Oncolytic viruses as therapeutic cancer vaccines.

Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30

Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. J Exp Clin Cancer Res (2016) 1.45

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front Oncol (2014) 1.29

Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res (2014) 1.23

Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22

Oncolytic viruses as anticancer vaccines. Front Oncol (2014) 1.13

Viruses for tumor therapy. Cell Host Microbe (2014) 1.09

Oncolysis by paramyxoviruses: preclinical and clinical studies. Mol Ther Oncolytics (2015) 0.95

Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. Mol Ther Oncolytics (2015) 0.94

Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer (2016) 0.90

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Mol Ther (2014) 0.89

Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells. BMC Cancer (2014) 0.88

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. Viruses (2015) 0.87

Nanotechnology: Future of Oncotherapy. Clin Cancer Res (2015) 0.86

Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol (2016) 0.85

Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer. Front Oncol (2014) 0.85

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Viruses (2016) 0.85

Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer (2016) 0.85

IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity. Cell Death Dis (2015) 0.83

Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget (2016) 0.82

Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land. Cancer Gene Ther (2014) 0.82

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Oncoimmunology (2015) 0.82

Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy. Cancer Gene Ther (2016) 0.82

Herpes simplex viral vectors: late bloomers with big potential. Hum Gene Ther (2014) 0.81

Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco Targets Ther (2016) 0.81

Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients. Front Bioeng Biotechnol (2015) 0.81

Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No? J Cancer (2015) 0.81

Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res (2015) 0.80

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front Immunol (2017) 0.79

Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Mol Oncol (2015) 0.78

Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy. Ther Deliv (2015) 0.78

The induction of antigen-specific CTL by in situ Ad-REIC gene therapy. Gene Ther (2016) 0.78

The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget (2016) 0.78

Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy (2015) 0.78

The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. Biomedicines (2017) 0.78

From Benchtop to Bedside: A Review of Oncolytic Virotherapy. Biomedicines (2016) 0.78

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun (2017) 0.77

Gene therapy in epilepsy-is it time for clinical trials? Nat Rev Neurol (2014) 0.77

Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. Mol Ther (2016) 0.77

In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells. Gene Ther (2015) 0.77

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy. Oncolytic Virother (2015) 0.76

Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity. Gene Ther (2015) 0.76

Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters. J Transl Med (2016) 0.76

Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer. Int J Mol Sci (2017) 0.76

11R-P53 and GM-CSF Expressing Oncolytic Adenovirus Target Cancer Stem Cells with Enhanced Synergistic Activity. J Cancer (2017) 0.75

CANCER CONUNDRUM. J Oral Maxillofac Pathol (2016) 0.75

Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses. Hum Gene Ther (2014) 0.75

Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses. ILAR J (2016) 0.75

Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model. Mol Ther Oncolytics (2016) 0.75

Targeted breast cancer therapy by harnessing the inherent blood group antigen immune system. Oncotarget (2017) 0.75

Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator. Gene Ther (2015) 0.75

Elucidating drivers of oral epithelial dysplasia formation and malignant transformation to cancer using RNAseq. Oncotarget (2015) 0.75

The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options. Cancers (Basel) (2015) 0.75

Autophagy Gene Activity May Act As a Key Factor for Sensitivity of Tumor Cells to Oncolytic Vesicular Stomatitis Virus. Iran J Cancer Prev (2016) 0.75

Replication and Oncolytic Activity of an Avian Orthoreovirus in Human Hepatocellular Carcinoma Cells. Viruses (2017) 0.75

Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy. Oncolytic Virother (2015) 0.75

Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther (2014) 0.75

Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy. Front Oncol (2017) 0.75

Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. Immunotargets Ther (2014) 0.75

Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. Oncoimmunology (2016) 0.75

Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus. Mol Ther Methods Clin Dev (2017) 0.75

Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. Onco Targets Ther (2017) 0.75

Immune System, Friend or Foe of Oncolytic Virotherapy? Front Oncol (2017) 0.75

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. Curr Treat Options Oncol (2017) 0.75

Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas. Transl Oncol (2017) 0.75

Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase. Mol Ther Oncolytics (2017) 0.75

Editorial of the Special Issue: Oncolytic Viruses as a Novel Form of Immunotherapy for Cancer. Biomedicines (2017) 0.75

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy. Front Oncol (2017) 0.75

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90

The danger model: a renewed sense of self. Science (2002) 13.85

Cancer immunotherapy comes of age. Nature (2011) 12.35

Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54

Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06

Unveiling the roles of autophagy in innate and adaptive immunity. Nat Rev Immunol (2007) 7.43

Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26

Decoding the patterns of self and nonself by the innate immune system. Science (2002) 7.19

Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol (2008) 6.78

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Oncolytic virotherapy. Nat Biotechnol (2012) 5.79

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86

The interferon response circuit: induction and suppression by pathogenic viruses. Virology (2006) 4.56

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med (2007) 4.39

Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 3.80

Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76

Immune therapy for cancer. Annu Rev Immunol (2009) 3.71

Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ (2005) 2.91

The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol (2006) 2.90

Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat Immunol (2009) 2.80

Viral mechanisms of immune evasion. Immunol Today (2000) 2.74

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther (2008) 2.72

Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 2.72

Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res (2001) 2.68

Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol (2010) 2.65

Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst (2007) 2.46

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest (2007) 2.36

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res (2006) 2.27

PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev (2012) 2.24

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19

Cell death in the host response to infection. Cell Death Differ (2008) 2.19

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther (2007) 2.14

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res (2011) 2.10

Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res (2008) 2.05

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther (2003) 2.05

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ (2008) 2.01

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97

Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell (2011) 1.95

Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res (2005) 1.91

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther (2010) 1.91

Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol (2008) 1.89

Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87

Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res (2007) 1.86

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther (1999) 1.84

Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ (2008) 1.84

Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82

Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta (2008) 1.82

Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther (2008) 1.78

Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med (1967) 1.75

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A (2008) 1.73

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 1.69

Viruses and the autophagy machinery. Cell Cycle (2010) 1.68

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol (2010) 1.64

Analysis of the role of autophagy in replication of herpes simplex virus in cell culture. J Virol (2007) 1.63

Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst (2006) 1.63

Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells. Cell Death Differ (2009) 1.62

Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther (2011) 1.60

Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther (2008) 1.59

Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis (2009) 1.56

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res (2013) 1.55

Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther (2009) 1.54

Autophagy and its role in MHC-mediated antigen presentation. J Immunol (2009) 1.54

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med (2012) 1.52

Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther (2010) 1.51

Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res (2012) 1.48

Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res (2006) 1.47

Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46

Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther (1999) 1.43

Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ (2013) 1.39

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother (2007) 1.38

Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res (2007) 1.37

Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol (2006) 1.37

Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res (2012) 1.36

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34

Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res (2013) 1.33

Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res (2008) 1.33

Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res (2010) 1.32

Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther (2006) 1.32

Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res (2012) 1.29

HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther (2005) 1.28

Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res (2010) 1.27

A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics (2007) 1.27

Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res (2005) 1.26

Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ (2013) 1.25

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res (2006) 1.23

Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther (2009) 1.22

Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther (2013) 1.22

Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther (2008) 1.21

Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 3.35

Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88

Meckel's diverticulum--a high-risk region for malignancy in the ileum. Insights from a population-based epidemiological study and implications in surgical management. Ann Surg (2011) 2.56

Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol (2010) 1.47

Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol (2008) 1.18

C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst (2011) 1.16

Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol (2010) 1.15

Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol (2012) 1.12

High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine (2004) 1.10

Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol (2014) 1.10

CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg (2013) 1.07

Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res (2013) 1.01

Gadd45b and Gadd45g are important for anti-tumor immune responses. Eur J Immunol (2009) 1.00

Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J Immunol (2009) 0.99

Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. PLoS One (2012) 0.99

Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol (2013) 0.95

Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice. Vaccine (2011) 0.92

Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization. J Immunol (2013) 0.89

Phagocytosis induces lysosome remodeling and regulated presentation of particulate antigens by activated dendritic cells. J Immunol (2006) 0.88

Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma. J Immunol (2011) 0.87

A fatal case of nafcillin-induced hepatotoxicity: a case report and the literature review. Case Rep Med (2012) 0.87

A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis. Mol Ther (2013) 0.85

Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. Int J Oncol (2013) 0.85

Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum Gene Ther (2002) 0.84

Mucin as a therapeutic target in pseudomyxoma peritonei. J Surg Oncol (2012) 0.82

Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Mol Ther (2011) 0.81

Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology (2014) 0.80

Pancreatic cancer: BRCA mutation and personalized treatment. Expert Rev Anticancer Ther (2015) 0.80

The recombinant immunogen with high-density epitopes of ELDKWA and ELDEWA induced antibodies recognizing both epitopes on HIV-1 gp41. Microbiol Immunol (2005) 0.78

Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization. J Immunol (2012) 0.76

Inhibition of HIV derived lentiviral production by TAR RNA binding domain of TAT protein. Retrovirology (2005) 0.76

Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin. Ann Surg Oncol (2012) 0.75

A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade. Immunol Lett (2002) 0.75